Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Extraordinary professor appointed
2005-11-10

UFS appoints its first extraordinary professor for health systems research and development  

 

 

Prof Dingie van Rensburg (Director: Centre for Health Systems Research and Development at the UFS) and Prof  Helen Schneider (senior researcher at the University of the Witwatersrand's Centre for Health Policy and extraordinary professor at the UFS Centre for Health Systems Research and Development). Photo: L Loader

 

The Centre for Health Systems Research and Development (CHSR&D) at the University of the Free State (UFS) has appointed its first extraordinary professor. 

Prof Helen Schneider, former director of the Centre for Health Policy at the University of the Witwatersrand (WITS) and currently senior researcher in that Centre and consultant in the WITS School of Public Health, was appointed by CHSR&D for a period of two years.

“Prof Schneider is widely known for her thorough experience, expertise and exposure in the field of public health, health policy and management and health policy and systems research.  We are honoured to have her join us as an extraordinary professor,”  said Prof Dingie van Rensburg, Director of CHSR&D.

Prof Schneider will be involved in various components of the CHSR&D’s long-term project on public sector anti-retroviral treatment (ART) and will also assist in the documenting, monitoring, evaluating and facilitation of the implementation of the national treatment plan in the Free State.  She is also assisting the Gauteng Department of Health in a similar way.

“The two provinces are actually so different.  They provide a different window on the realities of HIV/AIDS and the intellectual traditions involved in it,” said Prof Schneider.  “I hope to contribute meaningfully to finding new dimensions for research necessary in order to optimise the contribution and effect of the research on ART,” said Prof Schneider.

Another need for Prof Schneider’s appointment is to strengthen the senior research capacity of the CHSR&D, guide them with the ART project and assist in the implementation of research results into policy, management and practice.

Media release
Issued by:Lacea Loader
Media Representative
Tel:  (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
9 November 2005

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept